Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial results

PADN-HF-PH Trial Results Published in NEJM

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 03, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The publication of positive trial results in a top medical journal is likely to boost Pulnovo Medical's credibility and accelerate adoption of its PADN system, potentially increasing its market share in the pulmonary hypertension treatment space. Competitors in the heart failure and pulmonary hypertension device market may face increased pressure as PADN gains clinical validation.

Medical Devices Biotechnology Healthcare

Pulnovo Medical announced that results from the PADN-HF-PH trial were presented at the European Society of Endocrinology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine (NEJM). The multicenter, randomized, controlled trial involved 264 patients with pulmonary hypertension associated with left heart disease (PH-LHD). The trial evaluated the addition of Pulmonary Artery Denervation (PADN) to Guideline-Directed Medical Therapy (GDMT). Results showed a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and improvements in functional capacity and biomarkers. The therapy has regulatory approvals in 12 countries and has been referenced in seven clinical guidelines. The publication marks a significant milestone for cardiovascular interventions and provides evidence for a new treatment paradigm for PH-LHD.

100 Pulnovo Medical announced results
priv
Pulnovo Medical is the developer of the PADN system and sponsor of the trial. The positive results and NEJM publication are expected to enhance its commercial prospects and regulatory momentum.
Importance 100.0 Sentiment 90.0
ngo
The ESC Congress served as the venue for presenting the trial results, adding to its scientific program but with no direct financial impact.
Importance 40.0 Sentiment 10.0
per
Lead investigator of the PADN-HF-PH trial, playing a central role in its design and conduct.
Importance 40.0 Sentiment 5.0
priv
The trial was led by Academician Yaling Han from this hospital, which played a key role in the study's execution.
Importance 30.0 Sentiment 5.0
per
Co-corresponding author of the NEJM paper, contributing to the trial's scientific leadership.
Importance 30.0 Sentiment 5.0
per
Co-corresponding author, lending international credibility to the trial results.
Importance 30.0 Sentiment 5.0
priv
One of the co-corresponding authors is affiliated with this hospital, contributing to the trial's academic credibility.
Importance 20.0 Sentiment 5.0
ngo
Co-authored the 2022 guidelines that referenced PADN as an investigational therapy, providing context but not directly involved in this trial.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.